Simulations Plus is no longer a growth-software debate. Affiliates of Altaris, a healthcare-focused private-equity firm, agreed in mid-June to buy the biosimulation specialist for cash and fold it into Chemical Computing Group, an existing Altaris molecular-design platform. The board backed the sale unanimously. The founding Woltosz family locked a voting agreement covering a mid-teens stake, and shareholders approved the merger in late August by a landslide. The public-market argument that used to sit in the software mix, the renewal rate, and the artificial-intelligence narrative has been replaced by a close-versus-break question.
The sale is the logical end of a year in which the public franchise lost its growth premium. Software revenue was flat in the May quarter and slightly lower over nine months, even as services jumped on development-project demand. A year earlier the company wrote down most of the Pro-ficiency clinical-training acquisition, dismissed and then rehired auditors amid a segment-reporting fight, and cut the workforce. That sequence is why a cash bid at a modest premium to the sixty-day average looked like certainty rather than a cheap sale of a still-intact compounder.
The May-quarter print itself was clean enough on the operating line. Total revenue rose, gross margin recovered after the prior-year charge, and operating cash continued to pile up on a nearly debt-free balance sheet. The remaining live condition is French regulatory clearance tied to the Lixoft and MonolixSuite operations in Antony. Shares recently changed hands a few cents below the agreed cash price. That cash price is $18.50 per share. Residual holders are watching whether French clearance arrives in calendar fourth quarter, or whether a break sends the equity back to a software franchise that no longer grows.